Loss narrows sharply. Verrica Pharmaceuticals (NASDAQ: VRCA) reported Q4 2025 adjusted loss of $0.51 per share, narrowing 71.7% from the year-ago loss of $1.81 per share. Revenue of $5.1 million surged multifold from $344,000 in Q4 2024, marking the biotechnology company’s fourth consecutive quarter of year-over-year revenue growth. The company reported a GAAP net loss of $8.1 million, or $0.57 per diluted share, compared to a loss of $16.2 million. Cost of product revenue totaled $675,000 for the quarter.
Volatile trajectory persists. The Q4 results cap an erratic fiscal 2025 for Verrica, with quarterly EPS swinging from a loss in Q1 to profits in Q2 and Q3, before returning to a loss of $0.51 in Q4. Revenue followed a similarly uneven path, climbing from $3.4 million in Q1 to peaks of $12.7 million and $14.3 million in Q2 and Q3, respectively, before retreating sequentially to $5.1 million in Q4. Despite the quarter-to-quarter volatility, the year-over-year comparison shows meaningful progress. The company’s shares traded at $5.68 following the earnings report, within the 52-week range of $3.28 to $9.82, on volume of 271,185 shares.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.